Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia

the Marzeptacog alfa (activated) Study Group Investigators

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Fingerprint Dive into the research topics of 'Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia'. Together they form a unique fingerprint.

Medicine & Life Sciences